Two Sigma Advisers LP bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,076 shares of the biotechnology company’s stock, valued at approximately $734,000. Two Sigma Advisers LP owned approximately 0.07% of REGENXBIO at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of REGENXBIO by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 248,328 shares of the biotechnology company’s stock valued at $8,256,000 after buying an additional 2,506 shares in the last quarter. Nationwide Fund Advisors lifted its position in shares of REGENXBIO by 7.4% during the 3rd quarter. Nationwide Fund Advisors now owns 52,725 shares of the biotechnology company’s stock valued at $1,737,000 after buying an additional 3,651 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of REGENXBIO by 28.4% during the 4th quarter. SG Americas Securities LLC now owns 24,116 shares of the biotechnology company’s stock valued at $802,000 after buying an additional 5,339 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of REGENXBIO by 4.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 128,187 shares of the biotechnology company’s stock valued at $4,263,000 after buying an additional 5,678 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of REGENXBIO during the 4th quarter valued at approximately $302,000. Hedge funds and other institutional investors own 69.22% of the company’s stock.
In related news, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $26.56, for a total value of $265,600.00. Following the completion of the transaction, the insider now directly owns 238,530 shares of the company’s stock, valued at approximately $6,335,356.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Curran Simpson sold 25,000 shares of the stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $33.00, for a total value of $825,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,000 shares of company stock valued at $2,539,400. 17.00% of the stock is owned by corporate insiders.
REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.20. REGENXBIO had a negative return on equity of 36.48% and a negative net margin of 704.02%. The firm had revenue of $2.04 million during the quarter. equities analysts predict that REGENXBIO Inc. will post -2.5 earnings per share for the current year.
A number of brokerages have recently issued reports on RGNX. Zacks Investment Research lowered REGENXBIO from a “buy” rating to a “sell” rating in a research report on Tuesday. Alex. Brown set a $45.00 target price on REGENXBIO and gave the company a “buy” rating in a research report on Wednesday, April 11th. Chardan Capital increased their target price on REGENXBIO from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, April 9th. ValuEngine upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Finally, Morgan Stanley decreased their target price on REGENXBIO from $36.00 to $35.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. REGENXBIO presently has a consensus rating of “Buy” and a consensus price target of $42.00.
COPYRIGHT VIOLATION WARNING: “Two Sigma Advisers LP Takes Position in REGENXBIO Inc. (RGNX)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://stocknewstimes.com/2018/04/18/two-sigma-advisers-lp-takes-position-in-regenxbio-inc-rgnx.html.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.